

CTAGE4/6/9 (C-18): sc-323759

BACKGROUND

Cutaneous T cell lymphomas (CTCL) represent a group of malignancies that originate from CD4-T lymphocytes and manifest on the skin. CTCL is a general term for several neoplasms including mycosis fungoides, T cell leukemia/lymphoma and pagetoid reticulosis, all of which are very difficult to treat in the advanced stages. CTAGE4 (cutaneous T-cell lymphoma-associated antigen 4), CTAGE6 and CTAGE9 are all 777 amino acid single-pass membrane proteins that belong to the CTAGE family. All three proteins are found in CTCLs and are encoded by genes that map to human chromosome 7. Chromosome 7 houses over 1,000 genes, comprises nearly 5% of the human genome and has been linked to osteogenesis imperfecta, Pendred syndrome, lissencephaly, citrullinemia and Shwachman-Diamond syndrome.

REFERENCES

1. Tspirouras, P., et al. 1983. Restriction fragment length polymorphism associated with the pro α 2(I) gene of human type I procollagen. Application to a family with an autosomal dominant form of osteogenesis imperfecta. *J. Clin. Invest.* 72: 1262-1267.
2. Iwasaki, S., et al. 2001. Long-term audiological feature in Pendred syndrome caused by PDS mutation. *Arch. Otolaryngol. Head Neck Surg.* 127: 705-708.
3. Eichmüller, S., et al. 2001. Serological detection of cutaneous T-cell lymphoma-associated antigens. *Proc. Natl. Acad. Sci. USA* 98: 629-634.
4. Eichmüller, S. 2002. Towards defining specific antigens for cutaneous lymphomas. *Onkologie* 25: 448-454.
5. Eichmüller, S., et al. 2003. Tumor-specific antigens in cutaneous T-cell lymphoma: expression and sero-reactivity. *Int. J. Cancer* 104: 482-487.
6. Usener, D., et al. 2003. cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. *J. Invest. Dermatol.* 121: 198-206.

CHROMOSOMAL LOCATION

Genetic locus: CTAGE4/CTAGE6P/CTAGE15P (human) mapping to 7q35.

SOURCE

CTAGE4/6/9 (C-18) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of CTAGE6 of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-323759 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

CTAGE4/6/9 (C-18) is recommended for detection of CTAGE4, CTAGE6, CTAGE9 and LOC441294 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with CTAGE1, CTAGE3 or CTAGE5.


Molecular Weight of CTAGE4/6/9: 88 kDa.

Positive Controls: Jurkat whole cell lysate: sc-2204.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

DATA



CTAGE4/6/9 (C-18): sc-323759. Western blot analysis of CTAGE4/6/9 expression in Jurkat whole cell lysate.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.